This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

EORTC trial opens for patients with recurrent grade II or III meningioma

September 2nd, 2015

Meningiomas are a type of brain tumor that form on membranes covering the brain and spinal cord just inside the skull. They occur at an annual incidence of up to 13 per 100 000, and approximately 20% of these exhibit aggressive behavior and burden patients with tumor recurrences as well as infiltration of the surrounding bone, brain, or soft tissue.

Dr. Matthias Preusser of the Medical University Vienna - General Hospital AKH and Coordinator of this study says, "High-grade meningiomas are characterized by prominent infiltration with tumor-associated macrophages and angiogenesis. These characteristics, however, are among the therapeutic targets of trabectedin."

The aim of the recently opened comparative randomized phase II EORTC 1320 trial is to analyze prospectively collected data on activity, safety and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.

Dr. Preusser adds, "In fact, we saw very promising activity of trabectedin against meningioma cell lines in laboratory investigations and favorable disease stabilization in a patient with heavily pretreated malignant meningioma, and these findings provide us with a rationale for further studying the potential efficacy of trabectedin in grade II or III meningioma."

Provided by European Organisation for Research and Treatment of Cancer

Citation: EORTC trial opens for patients with recurrent grade II or III meningioma (2015, September 2) retrieved 28 March 2024 from https://sciencex.com/wire-news/202650248/eortc-trial-opens-for-patients-with-recurrent-grade-ii-or-iii-me.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.